Out of 33 evaluable patients with advanced ovarian cancer, resistant to extensive poly-chemotherapy, then treated with high-dose im medroxyprogesterone (MPA), five partial responses (15%) were obtained. No partial response was obtained in a comparable group of 30 patients treated with an oral schedule. Four patients (two po, 2 im) had stable disease for at least 3 months, and 16 experienced subjective improvement. Treatment was very well tolerated. This study shows that high-dose MPA has some activity in ovarian cancer, and is worthy of further investigation.
High-dose medroxyprogesterone acetate (MPA) in advanced epithelial ovarian cancer resistant to first- or second-line chemotherapy / C. Mangioni, S. Franceschi, C. La Vecchia, M. D'Incalci. - In: GYNECOLOGIC ONCOLOGY. - ISSN 0090-8258. - 12:3(1981 Dec), pp. 314-318.
Titolo: | High-dose medroxyprogesterone acetate (MPA) in advanced epithelial ovarian cancer resistant to first- or second-line chemotherapy |
Autori: | LA VECCHIA, CARLO VITANTONIO BATTISTA (Penultimo) |
Parole Chiave: | Administration, Oral; Ovarian Neoplasms; Antineoplastic Agents; Delayed-Action Preparations; Humans; Injections, Intramuscular; Adult; Aged; Middle Aged; Medroxyprogesterone; Medroxyprogesterone Acetate; Female |
Settore Scientifico Disciplinare: | Settore MED/01 - Statistica Medica |
Data di pubblicazione: | dic-1981 |
Rivista: | |
Tipologia: | Article (author) |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1016/0090-8258(81)90131-1 |
Appare nelle tipologie: | 01 - Articolo su periodico |